title: Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
abstract: The aim of this study was to evaluate whether body weight changes in patients undergoing chemotherapy for epithelial ovarian cancer (EOC) influence progression-free survival (PFS) and overall survival (OS).
  
  
  
  An analysis of 190 patients diagnosed with ovarian cancer after first-line chemotherapy was conducted. Changes in body weight were assessed by comparing measurements at baseline to those of the third and sixth cycles of chemotherapy. PFS and OS were calculated with the Kaplan-Meier method and multivariate Cox model.
  
  
  
  Significant reduction in body weight in advanced EOC was observed with no changes in early EOC. Significant differences in PFS were observed in advanced EOC patients that lost more than 5 % of their body weight (6 months), maintained weight (13 months), or gained more than 5 % of their body weight (15 months). Similarly, significant differences in OS were noted in advanced EOC at the following time points: 24.3, 42.4, and 66.2 months. No effect was reported for early EOC patients. The multivariate Cox analysis showed significant body weight changes from the first to the sixth chemotherapy cycle for PFS (HR = 0.97; 95 % CI 0.95-0.99) and OS (HR = 0.94; 95 % CI 0.91-0.97) as well as from the first to the third chemotherapy cycle for OS (HR = 0.93; 95 % CI 0.88-0.98).
  
  
  
  Body weight changes can be recognized as a prognostic factor for PFS and OS in advanced EOC patients undergoing chemotherapy. Weight loss is associated with poorer survival while weight gain improved outcomes.
authors: Department of Oncology, Poznan University of Medical Sciences, Szamarzewskiego Str 82/84, 60-569, Poznan, Poland.|Department of Human Nutrition and Hygiene, Poznan University of Life Science, Wojska Polskiego Str 28, 60-637, Poznan, Poland.
authors: Marcin
authors: M
authors: Mardas
authors: Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Arthur-Scheunert Allee 114-116, 14558, Nuthetal, Germany. stelmach@dife.de.|Department of Pediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Sciences, Szpitalna Str 27/33, 60-572, Poznan, Poland. stelmach@dife.de.
authors: Marta
authors: M
authors: Stelmach-Mardas
authors: Department of Oncology, Poznan University of Medical Sciences, Szamarzewskiego Str 82/84, 60-569, Poznan, Poland.
authors: Radosław
authors: R
authors: Madry
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001835:Body Weight / Q000502:physiology*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000503:physiopathology; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000503:physiopathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D015430:Weight Gain / Q000502:physiology; D015431:Weight Loss / Q000502:physiology
keywords: Body mass; Ovarian cancer; Prognostic factor; Survival